Ghent University Academic Bibliography

Advanced

Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous-cell carcinoma of the head and neck

DAVID LOOSE UGent, Alberto Signore, Elena Bonanno, Hubert Vermeersch UGent, Rudi Dierckx UGent, PHILIPPE DERON UGent and Christophe Van De Wiele UGent (2008) CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 23(1). p.25-33
abstract
CD4(+)CD25(+) T-cells play a central role in initiating and maintaining anticancer immune response. On the other hand, CD25(+) is also expressed on tumor cells, the meaning of which is currently unclear. Therefore, this study was designed to determine the prognostic value of the presence of CD4(+)CD25(+) T-cells in squamous-cell carcinoma of the head and neck (SCCHN) and of CD25 on SCCHN tumor cells. Thirty-five (35) patients diagnosed with a primary untreated SCCHN were included in this study. Instantly snap-frozen resection or biopsy specimens were analyzed by immunohistochemistry. Histologic results obtained were related to overall, disease-free survival. On univariate analysis, both lymph-node status and the number of CD25(+) lymphocytes were associated with disease-free survival (p = 0.039 and 0.04). On multivariate analysis, only the number of CD25(+) lymphocytes showed an association with disease-free survival (p = 0.036), whereas both factors showed an independent association with overall survival (p = 0.007 and 0.003). Contrarywise, the CD25 expression on SCCHN tumor cells was not associated with disease-free survival nor with overall survival. The presence of a high number of SCCHN-infiltrating CD4(+)CD25(+) lymphocytes is associated with a good prognosis in SCCHN patients. Contrarywise, the CD25 expression on SCCHN tumor cells is not associated with a prognosis in SCCHN patients, and its role and meaning remains to be elucidated.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
journal title
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
Cancer Biother. Radiopharm.
volume
23
issue
1
pages
25 - 33
Web of Science type
Article
Web of Science id
000254025100003
JCR category
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
JCR impact factor
1.318 (2008)
JCR rank
63/90 (2008)
JCR quartile
3 (2008)
ISSN
1084-9785
DOI
10.1089/cbr.2007.0373
language
English
UGent publication?
yes
classification
A1
id
503908
handle
http://hdl.handle.net/1854/LU-503908
date created
2009-02-20 12:39:45
date last changed
2009-02-24 13:28:43
@article{503908,
  abstract     = {CD4(+)CD25(+) T-cells play a central role in initiating and maintaining anticancer immune response. On the other hand, CD25(+) is also expressed on tumor cells, the meaning of which is currently unclear. Therefore, this study was designed to determine the prognostic value of the presence of CD4(+)CD25(+) T-cells in squamous-cell carcinoma of the head and neck (SCCHN) and of CD25 on SCCHN tumor cells. Thirty-five (35) patients diagnosed with a primary untreated SCCHN were included in this study. Instantly snap-frozen resection or biopsy specimens were analyzed by immunohistochemistry. Histologic results obtained were related to overall, disease-free survival. On univariate analysis, both lymph-node status and the number of CD25(+) lymphocytes were associated with disease-free survival (p = 0.039 and 0.04). On multivariate analysis, only the number of CD25(+) lymphocytes showed an association with disease-free survival (p = 0.036), whereas both factors showed an independent association with overall survival (p = 0.007 and 0.003). Contrarywise, the CD25 expression on SCCHN tumor cells was not associated with disease-free survival nor with overall survival. The presence of a high number of SCCHN-infiltrating CD4(+)CD25(+) lymphocytes is associated with a good prognosis in SCCHN patients. Contrarywise, the CD25 expression on SCCHN tumor cells is not associated with a prognosis in SCCHN patients, and its role and meaning remains to be elucidated.},
  author       = {LOOSE, DAVID and Signore, Alberto and Bonanno, Elena and Vermeersch, Hubert and Dierckx, Rudi and DERON, PHILIPPE and Van De Wiele, Christophe},
  issn         = {1084-9785},
  journal      = {CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS},
  language     = {eng},
  number       = {1},
  pages        = {25--33},
  title        = {Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous-cell carcinoma of the head and neck},
  url          = {http://dx.doi.org/10.1089/cbr.2007.0373},
  volume       = {23},
  year         = {2008},
}

Chicago
LOOSE, DAVID, Alberto Signore, Elena Bonanno, Hubert Vermeersch, Rudi Dierckx, PHILIPPE DERON, and Christophe Van De Wiele. 2008. “Prognostic Value of CD25 Expression on Lymphocytes and Tumor Cells in Squamous-cell Carcinoma of the Head and Neck.” Cancer Biotherapy and Radiopharmaceuticals 23 (1): 25–33.
APA
LOOSE, D., Signore, A., Bonanno, E., Vermeersch, H., Dierckx, R., DERON, P., & Van De Wiele, C. (2008). Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous-cell carcinoma of the head and neck. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 23(1), 25–33.
Vancouver
1.
LOOSE D, Signore A, Bonanno E, Vermeersch H, Dierckx R, DERON P, et al. Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous-cell carcinoma of the head and neck. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS. 2008;23(1):25–33.
MLA
LOOSE, DAVID, Alberto Signore, Elena Bonanno, et al. “Prognostic Value of CD25 Expression on Lymphocytes and Tumor Cells in Squamous-cell Carcinoma of the Head and Neck.” CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 23.1 (2008): 25–33. Print.